We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

133 hedge funds and large institutions have $485M invested in Cymabay Therapeutics in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 29 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

511% more call options, than puts

Call options by funds: $7.81M | Put options by funds: $1.28M

86% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 29

6% less funds holding

Funds holding: 142 → 133 (-9)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

47% less capital invested

Capital invested by funds: $907M → $485M (-$422M)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
133
Holders Change
-9
Holders Change %
-6.34%
% of All Funds
2.89%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.04%
New
25
Increased
54
Reduced
29
Closed
32
Calls
$7.81M
Puts
$1.28M
Net Calls
+$6.53M
Net Calls Change
+$5.77M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$44.1M
2
ACA
Avoro Capital Advisors
New York
+$22.4M
3
Millennium Management
Millennium Management
New York
+$14.5M
4
Citigroup
Citigroup
New York
+$6.37M
5
BlackRock
BlackRock
New York
+$5.59M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$24.9M
2
GPP
Great Point Partners
Connecticut
-$13.3M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$11.1M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10.5M
5
CS
Credit Suisse
Switzerland
-$8.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
State Board of Administration of Florida Retirement System
101
State Board of Administration of Florida Retirement System
Florida
$89K +$2.04K +180 +1%
AB
102
Amalgamated Bank
New York
$87K +$138K +12,219 New
Canada Life
103
Canada Life
Manitoba, Canada
$81K +$57.8K +5,100 +81%
Cambridge Investment Research Advisors
104
Cambridge Investment Research Advisors
Iowa
$80K +$127K +11,200 New
TAM
105
Tiverton Asset Management
Delaware
$57K – – –
Bank of Montreal
106
Bank of Montreal
Ontario, Canada
$48K +$71.5K +6,311 +1,372%
BNP Paribas Financial Markets
107
BNP Paribas Financial Markets
France
$47.9K -$65.1K -5,747 -46%
Morgan Stanley
108
Morgan Stanley
New York
$45K -$295K -26,046 -80%
CG
109
Cutler Group
California
$37K +$58.9K +5,200 New
AIP
110
Ameritas Investment Partners
Nebraska
$35K – – –
Zurich Cantonal Bank
111
Zurich Cantonal Bank
Switzerland
$29K – – –
RIA
112
Realta Investment Advisors
Delaware
$24K +$19.3K +1,700 +100%
Federated Hermes
113
Federated Hermes
Pennsylvania
$24K +$32.6K +2,883 +667%
FCM
114
Flinton Capital Management
Pennsylvania
$19K – – –
QT
115
Quantbot Technologies
New York
$18K +$30K +2,647 New
TAM
116
Tyers Asset Management
Texas
$16K – – –
MAM
117
Meeder Asset Management
Ohio
$14K -$9.61K -849 -30%
NA
118
Neuburgh Advisers
California
$12K – – –
MCIM
119
Meadow Creek Investment Management
Georgia
$9K – – –
Victory Capital Management
120
Victory Capital Management
Texas
$9K – – –
APA
121
American Portfolios Advisors
New York
$5.23K +$4.3K +380 +109%
PCM
122
Prelude Capital Management
New York
$5K +$8.69K +767 New
TC
123
Truvestments Capital
Florida
$4K – – –
AG
124
Advisor Group
Arizona
$3K -$25.3K -2,233 -86%
Daiwa Securities Group
125
Daiwa Securities Group
Japan
$3K – – –
3 4
5
6 7

CBAY Hedge Fund Activity: Q2 2019 in Review

133 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2019, worth a combined $485M — down 47% from $907M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of CBAY and 25 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 54 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $44.1M. The largest seller was OrbiMed, exiting entirely with an estimated $24.9M sold.

  • 133 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2019, down from 142 in Q1 2019.
  • Funds reported $485M of Cymabay Therapeutics stock for Q2 2019, down 47% quarter-over-quarter.
  • 25 funds opened new Cymabay Therapeutics positions in Q2 2019 and 32 closed out, a net change of -7 holders.
  • The largest Cymabay Therapeutics buyer in Q2 2019 was Point72 Asset Management, an estimated $44.1M added.
  • The largest Cymabay Therapeutics seller in Q2 2019 was OrbiMed, an estimated $24.9M sold.

Based on aggregated 13F filings for Q2 2019.